Industries > Pharma > Global Melanoma Drugs Market 2018-2028

Global Melanoma Drugs Market 2018-2028

By Kinase Inhibitors, by Immunotherapeutic Agents, by Chemotherapeutic Agents, Tafinlar, Mekinist, Zelbroaf, Yervoy, Proleukin, Keytruda, PegIntron, Roferon-A, Dacarbazine, Temodar/Temodal and Leading Companies

PUBLISHED: 17 April 2018
PAGES: 149
PRODUCT CODE: PHA0301
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0301 Categories: , Tags: , ,

Melanoma Drugs – new study showing you trends, R&D progress, and predicted revenues
Where is the melanoma drugs market heading? What are the commercial prospects for this market and related technologies? Visiongain’s new report shows you potential revenues and other trends to 2028, discussing data, opportunities and prospects.

Our new 149-page report provides 161 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2018-2028 and other analyses show you commercial prospects
Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces), company profiles and commercial developments.

You find prospects for key submarkets
In addition to analyses of the overall world market, you see revenue forecasts for these four submarkets to 2028:
• Chemotherapeutic melanoma drugs
• Kinase Inhibitors
• Immunotherapeutic melanoma drugs
• Other melanoma drugs

Drugs that can significantly increase disease-free and progression-free survival while also improving patient tolerance will achieve success. Combination therapies aimed at attacking melanoma from multiple angles will prove successful in providing added benefits to patients and manufacturers.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find the dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2028 at the world level? How will promising products currently in the pipeline perform once they are launched? Our study forecasts sales of 9 melanoma products including these:
• Dabrafenib (Tafinlar)
• Trametinib (Mekinist)
• Vemurafenib (Zelboraf)
• Ipilimumab (Yervoy)
• PegIntron (Sylatron)
• Proleukin (Aldesleukin)
• Pembrolizumab (Keytruda)
• Dacarbzine (DTIC-Dome)
• Temodar/Temodal (Temozolomide)

Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

What are the prospects for the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 20 national markets to 2028:
• US
• Canada
• Mexico
• Brazil
• Argentina
• Paraguay
• Bolivia
• France
• Germany
• UK
• Spain
• Italy
• Russia
• China
• Japan
• India
• Australia
• Thailand
• Middle East
• Africa

Global Melanoma Drugs Market 2018-2028

Our analyses show sustained growth, particularly for the markets with high predisposition factors to melanoma such as in Australia, Europe, and the Americas. New product approvals and the development of innovative targeted therapies will influence market growth.

Regulatory, demographic, and commercial developments worldwide will influence the markets both in the established North American and Western European economies, and the fast-rising emerging markets.

Leading companies and potential for market growth
Overall world revenue for melanoma drugs will reach $89bn in 2018, our work forecasts. Rising demand for melanoma drugs, expanding healthcare coverage, recently launched therapies and a strong R&D pipeline will increase sales to 2028.

Our work shows you what organisations hold greatest potential. See profiles of 10 leading companies, including these:
• Novartis
• Bristol Myers Squibb
• Bayer
• Sanofi
• GSK
• AstraZeneca
• Amgen
• Roche
• Merck & Co.
• Celgene

A company profile gives you the following information:
• Recent financial results
• company’s activities and outlook, including oncology product portfolios and pipelines
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development activities
What is happening in the R&D pipeline for melanoma drugs? You see developmental trends, gaining insight into the R&D pipeline for:
• Kinase inhibitors for melanoma
• Immunotherapeutic agents for melanoma
• Vaccines for melanoma
• Genetic therapies for melanoma
• Other therapies for melanoma treatment

What issues will affect the melanoma drugs market?
Our new report discusses issues and events affecting the melanoma drugs market. You will find discussions of many issues and developments, including:
• Reimbursement, regulations, patent expiries, generic competition
• Cost savings and efficiencies
• The use of biologics, targeted and combination therapies
• Understanding melanoma aetiology and progression
• Safety and patient compliance
• Clinical evidence supporting product efficacy

Our investigation gives you multi-level business research and analyses with sales forecasts. You see how that industry and market can perform from 2018 to 2028.

How the Melanoma Drugs Market Forecast 2018-2028 report helps you
In summary our 149-page report gives you the following knowledge:
• Revenue forecasts to 2028 for the overall melanoma drugs market and 4 submarkets – discover the industry’s prospects, finding promising areas for investments and revenues
• Predicted revenues for 9 melanoma drugs – discover prospects for leading products in the market and promising therapies in the pipeline, with forecasted revenues provided to 2028
• Revenue forecast to 2028 for 20 leading national markets – US
Canada, Mexico, Brazil, Argentina, Paraguay, Bolivia, France, Germany, UK, Spain, Italy, Russia, China, Japan, India, Australia, Thailand, Middle East and Africa
• Evaluation of pipeline drugs – find the market potential for leading products currently in the development pipeline in each market segment  
• Assessment of 10 leading companies – hear about products, results and strategies, including recent activities and outlook for companies such as Merck, Novartis, GSK, Bristol Myers Squibb, and Roche
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities

You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for melanoma drugs. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Melanoma Drugs Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Global Melanoma Drugs Market 2018-2028


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories